Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$55.79 USD
+1.79 (3.31%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $55.76 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 121 - 140 ( 311 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q17 Results; Busy Bees as We Approach Pivotal Tirasemtiv Data; PT up to $26
Provider: Rodman & Renshaw, Co.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q17 Results; Busy Bees as We Approach Pivotal Tirasemtiv Data; PT up to $26
Provider: H.C. Wainwright & Co., Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
We are dropping coverage of CYTK shares to reallocate our research resources
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q17 Results; The Excitement Is Palpable; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q17 Results; The Excitement Is Palpable; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Early Looking Glass Into SMA Demand as We Remind About Upcoming CK-107 First Look; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Early Looking Glass Into SMA Demand as We Remind About Upcoming CK-107 First Look; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
A Few Cool Updates and Initial Phase 2 SMA Data in Mid-2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
A Few Cool Updates and Initial Phase 2 SMA Data in Mid-2017; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Initiating Coverage at Buy; $25 PT
Provider: Rodman & Renshaw, Co.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
It''s All About Something Different Happening; Initiating Coverage at Buy; $25 PT
Provider: H.C. Wainwright & Co., Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
We are transferring coverage of CYTK to Sa''ar Yaniv, due to the departure of the covering analyst and placing shares Under Review
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Liftoff for GALACTIC-HF (SPA); Oh, And a $26.7 Million Check
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
COSMIC-HF Expansion Phase Yields New Clinical Support
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q16 Results; It''s All About Execution Now For Broad Clinical Programs
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
VITALITY-ALS Morphs Into VIGORALS; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J